Dutasteride
Unchecked
Dutasteride
Avodart; combined with tamsulosin as Jalyn
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Benign prostatic hyperplasia0, Androgenetic alopecia (off-label, more potent than finasteride)0
Pharmacy
Starting dose
0.5 mg PO once daily
Preparations
0.5 mg capsules
US FDA Max
0.5 mg/d
Pharmacology
Routes
Oral
Onset
Prostate volume reduction over 6-12 months
Duration
24 hours; tissue effects persist weeks
Half-life
~5 weeks (much longer than finasteride's ~6 hours)[1]
Bioavailability
~60% (oral)[1]
Pregnancy
Pregnant individuals should not handle dutasteride capsules (skin absorption risk through intact capsule); can cause hypospadias in male fetus.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Dutasteride inhibits both type I (skin, hepatic) and type II (prostatic) 5α-reductase, achieving >90% serum DHT suppression compared with finasteride's ~70%; the dual inhibition translates to greater prostate volume reduction but a similar overall clinical effect in BPH.0 The long half-life means blood donation should be deferred for 6 months after the last dose (per FDA labeling) to prevent fetal exposure in a pregnant transfusion recipient. Post-finasteride/dutasteride syndrome (persistent sexual and mood effects after discontinuation) is a controversial but recognized clinical concern[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Avodart (dutasteride), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020180s045lbl.pdf